The H/Rouen mouse model displays depression-like and anxiety-like behaviors

Behavioural Brain Research

Volumn 256, Issue , 2013, Pages 43-50

  El Yacoubi, Malika ^a,b   Rappeneau, Virginie ^a,b   Champion, Eddy ^a,b   Malleret, Gaël ^a,b   Vaugeois, Jean Marie ^a,c  

^a LYON NEUROSCIENCE RESEARCH CENTER   (France)

^b UNIVERSITÉ LYON 1   (France)

^c UNIVERSITÉ DE ROUEN   (France)

Author keywords

Anhedonia; Animal model; Anxiety; Depressive disorder; Mouse; Tail suspension test

Indexed keywords

FLUOXETINE; SUCROSE; ANTIDEPRESSANT AGENT;

ANHEDONIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CHRONIC DRUG ADMINISTRATION; COMORBIDITY; DECISION MAKING; DEPRESSION; EXPERIMENTAL MODEL; FEMALE; FORCED SWIMMING TEST; HELPLESSNESS; IMMOBILIZATION; MALE; MAZE TEST; MOUSE; NONHUMAN; OPEN FIELD TEST; PHENOTYPE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; TREATMENT OUTCOME; ANIMAL; ANXIETY; COMPLICATION; DEPRESSIVE DISORDER; DISEASE MODEL; DRINKING BEHAVIOR; DRUG EFFECTS; EXPLORATORY BEHAVIOR; FOOD PREFERENCE; INBRED MOUSE STRAIN; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; SPECIES DIFFERENCE;

ANHEDONIA; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY; COMORBIDITY; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; DRINKING BEHAVIOR; EXPLORATORY BEHAVIOR; FEMALE; FLUOXETINE; FOOD PREFERENCES; MALE; MICE, INBRED STRAINS; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TESTS; SPECIES SPECIFICITY; SUCROSE;

EID: 84882958565     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.07.048     Document Type: Article

References (39)

1. Kessler R.C., McGonagle K.A., Zhao S., Nelson C.B., Hughes M., Eshleman S., et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry 1994, 51:8-19.
2. Breslau N., Chilcoat H., Schultz L.R. Anxiety disorders and the emergence of sex differences in major depression. Journal of Gender-Specific Medicine 1998, 1:33-39.
3. Belmaker R.H., Agam G. Major depressive disorder. New England Journal of Medicine 2008, 358:55-68.
4. Millan M.J. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics 2009, 6:53-77.
5. Fava M., Kendler K.S. Major depressive disorder. Neuron 2000, 28:335-341.
6. Henn F., McKinney T. Animal models in psychiatry. Psychopharmacology: The Third Generation of Progress 1987, 687-695. Raven Press, New York. H. Meltzer (Ed.).
7. Kendler K.S., Walters E.E., Truett K.R., Heath A.C., Neale M.C., Martin N.G., et al. Sources of individual differences in depressive symptoms: analysis of two samples of twins and their families. American Journal of Psychiatry 1994, 151:1605-1614.
8. Sham P.C., Sterne A., Purcell S., Cherny S., Webster M., Rijsdijk F., et al. GENESiS: creating a composite index of the vulnerability to anxiety and depression in a community-based sample of siblings. Twin Research 2000, 3:316-322.
9. Willner P. Animal models of depression: an overview. Pharmacology and Therapeutics 1990, 45:425-455.
10. Overstreet D.H., Pucilowski O., Rezvani A.H., Janowsky D.S. Administration of antidepressants, diazepam and psychomotor stimulants further confirms the utility of flinders sensitive line rats as an animal model of depression. Psychopharmacology 1995, 121:27-37.
11. Schiller G.D., Daws L.C., Overstreet D.H., Orbach J. Lack of anxiety in an animal model of depression with cholinergic supersensitivity. Brain Research Bulletin 1991, 26:433-435.
12. Landgraf R., Wigger A. High vs low anxiety-related behavior rats: an animal model of extremes in trait anxiety. Behavior Genetics 2002, 32:301-314.
13. Keck M.E., Welt T., Muller M.B., Uhr M., Ohl F., Wigger A., et al. Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model. Neuropsychopharmacology 2003, 28:235-243.
14. Kromer S.A., Kessler M.S., Milfay D., Birg I.N., Bunck M., Czibere L., et al. Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety. Journal of Neuroscience 2005, 25:4375-4384.
15. El Yacoubi M., Bouali S., Popa D., Naudon L., Leroux-Nicollet I., Hamon M., et al. Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:6227-6232.
16. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985, 85:367-370.
17. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends in Pharmacological Sciences 2002, 23:238-245.
18. Cryan J.F., Mombereau C., Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neuroscience and Biobehavioral Reviews 2005, 29:571-625.
19. Popa D., El Yacoubi M., Vaugeois J.M., Hamon M., Adrien J. Homeostatic regulation of sleep in a genetic model of depression in the mouse: effects of muscarinic and 5-HT1A receptor activation. Neuropsychopharmacology 2006, 31:1637-1646.
20. Svenningsson P., Chergui K., Rachleff I., Flajolet M., Zhang X., El Yacoubi M., et al. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 2006, 311:77-80.
21. Belzung C., Griebel G. Measuring normal and pathological anxiety-like behaviour in mice: a review. Behavioural Brain Research 2001, 125:141-149.
22. Hasler G., Drevets W.C., Manji H.K., Charney D.S. Discovering endophenotypes for major depression. Neuropsychopharmacology 2004, 29:1765-1781.
23. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology 1997, 134:319-329.
24. Naranjo C.A., Tremblay L.K., Busto U.E. The role of the brain reward system in depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2001, 25:781-823.
25. Loas G. Vulnerability to depression: a model centered on anhedonia. Journal of Affective Disorders 1996, 41:39-53.
26. Strekalova T., Spanagel R., Bartsch D., Henn F.A., Gass P. Stress-induced anhedonia in mice is associated with deficits in forced swimming and exploration. Neuropsychopharmacology 2004, 29:2007-2017.
27. Steru L., Chermat R., Thierry B., Mico J.A., Lenegre A., Steru M., et al. The automated tail suspension test: a computerized device which differentiates psychotropic drugs. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1987, 11:659-671.
28. El Yacoubi M., Vaugeois J.M., Marguet D., Sauze N., Guieu R., Costentin J., et al. Behavioral characterization of CD26 deficient mice in animal tests of anxiety and antidepressant-like activity. Behavioural Brain Research 2006, 171:279-285.
29. Suaudeau C., Rinaldi D., Lepicard E., Venault P., Crusio W.E., Costentin J., et al. Divergent levels of anxiety in mice selected for differences in sensitivity to a convulsant agent. Physiology and Behavior 2000, 71:517-523.
30. El Yacoubi M., Ledent C., Parmentier M., Costentin J., Vaugeois J.M. The anxiogenic-like effect of caffeine in two experimental procedures measuring anxiety in the mouse is not shared by selective A(2A) adenosine receptor antagonists. Psychopharmacology 2000, 148:153-163.
31. Strekalova T., Gorenkova N., Schunk E., Dolgov O., Bartsch D. Selective effects of citalopram in a mouse model of stress-induced anhedonia with a control for chronic stress. Behavioural Pharmacology 2006, 17:271-287.
32. Ressler K.J., Mayberg H.S. Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nature Neuroscience 2007, 10:1116-1124.
33. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron 2002, 34:13-25.
34. Jiao X., Pare W.P., Tejani-Butt S.M. Antidepressant drug induced alterations in binding to central dopamine transporter sites in the Wistar Kyoto rat strain. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2006, 30:30-41.
35. Ditzen C., Jastorff A.M., Kessler M.S., Bunck M., Teplytska L., Erhardt A., et al. Protein biomarkers in a mouse model of extremes in trait anxiety. Molecular and Cellular Proteomics 2006, 5:1914-1920.
36. Hascoet M., Bourin M., Dhonnchadha B.A. The mouse light-dark paradigm: a review. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2001, 25:141-166.
37. El Yacoubi M., Vaugeois J.M. Genetic rodent models of depression. Current Opinion in Pharmacology 2007, 7:3-7.
38. Muigg P., Hoelzl U., Palfrader K., Neumann I., Wigger A., Landgraf R., et al. Altered brain activation pattern associated with drug-induced attenuation of enhanced depression-like behavior in rats bred for high anxiety. Biological Psychiatry 2007, 61:782-796.
39. Monleon S., D'Aquila P., Parra A., Simon V.M., Brain P.F., Willner P. Attenuation of sucrose consumption in mice by chronic mild stress and its restoration by imipramine. Psychopharmacology 1995, 117:453-457.